Several research areas were identified in the course of the development of these guidelines:

• Pharmacokinetics, safety and efficacy studies in specific populations (infants and children, PL HIV (especially those on ART), alcohol and drug users, elderly persons, pregnant or breastfeeding women, persons with extrapulmonary TB, persons with diabetes);
• Safety studies, including type, frequency and severity of adverse events (short term and long term), and mortality (including cause of death);
• Drug-drug interaction studies with other existing and newly developed TB drugs (including Group 5 second line drugs) and ARVs; and the most frequently used drugs to manage adverse effects and other TB co-morbidities;
• Optimal dosing studies (including once daily dosing) and treatment duration studies;
• Acquisition of resistance to delamanid and to other TB drugs during treatment;
• Accurate, reproducible and affordable DST methods for delamanid;
• Effectiveness studies performed in various programmatic settings.